Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway

Doxorubicin (Dox)-induced cardiotoxicity, a limiting factor in the use of Dox to treat cancer, can be mitigated by the mitogenic factor FGF2 in vitro, via a heme oxygenase 1 (HO-1)-dependent pathway. HO-1 upregulation was reported to require protein kinase CK2 activity. We show that a mutant non-mit...

Descripción completa

Detalles Bibliográficos
Autores principales: Koleini, Navid, Nickel, Barbara E., Edel, Andrea L., Fandrich, Robert R., Ravandi, Amir, Kardami, Elissavet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267702/
https://www.ncbi.nlm.nih.gov/pubmed/30159756
http://dx.doi.org/10.1007/s00441-018-2905-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267702/
https://www.ncbi.nlm.nih.gov/pubmed/30159756
http://dx.doi.org/10.1007/s00441-018-2905-z

Ejemplares similares